Key Points
- Derek Maetzold sold 3,200 Castle Biosciences shares on Feb. 3 at an average price of $39.91 for $127,712, leaving him with 84,515 shares and a 3.65% reduction in ownership.
- Castle Biosciences reported quarterly results that beat expectations—($0.02) EPS vs. a consensus ($0.34) and $80.55M revenue vs. $71.06M—while still showing a small negative net margin.
- Analysts have mostly raised ratings and price targets recently, leaving a consensus of "Moderate Buy" with an average target of about $47.14.
Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) insider Derek Maetzold sold 817 shares of the business's stock in a transaction dated Wednesday, February 4th. The shares were sold at an average price of $37.99, for a total value of $31,037.83. Following the completion of the transaction, the insider owned 83,698 shares in the company, valued at $3,179,687.02. This trade represents a 0.97% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Castle Biosciences Stock Performance
Castle Biosciences stock traded up $0.68 during mid-day trading on Friday, reaching $33.08. 150,839 shares of the company were exchanged, compared to its average volume of 395,539. The firm has a market cap of $965.43 million, a PE ratio of -73.37 and a beta of 1.06. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.31 and a current ratio of 6.47. The firm's 50-day simple moving average is $39.51 and its two-hundred day simple moving average is $29.52. Castle Biosciences, Inc. has a twelve month low of $14.59 and a twelve month high of $44.28.
Castle Biosciences (NASDAQ:CSTL - Get Free Report) last issued its quarterly earnings results on Monday, November 3rd. The company reported ($0.02) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.32. Castle Biosciences had a positive return on equity of 1.73% and a negative net margin of 3.56%.The firm had revenue of $80.55 million during the quarter, compared to the consensus estimate of $71.06 million. Equities analysts predict that Castle Biosciences, Inc. will post 0.44 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Castle Biosciences
Hedge funds have recently bought and sold shares of the company. Farther Finance Advisors LLC raised its holdings in Castle Biosciences by 139,100.0% during the third quarter. Farther Finance Advisors LLC now owns 1,392 shares of the company's stock worth $32,000 after purchasing an additional 1,391 shares during the last quarter. State of Alaska Department of Revenue purchased a new position in shares of Castle Biosciences in the third quarter valued at $35,000. CWM LLC increased its position in shares of Castle Biosciences by 80.6% in the third quarter. CWM LLC now owns 1,911 shares of the company's stock valued at $44,000 after buying an additional 853 shares in the last quarter. Jones Financial Companies Lllp raised its stake in shares of Castle Biosciences by 10,592.0% during the 1st quarter. Jones Financial Companies Lllp now owns 2,673 shares of the company's stock worth $54,000 after buying an additional 2,648 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Castle Biosciences by 26.5% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,418 shares of the company's stock worth $55,000 after buying an additional 297 shares in the last quarter. 92.60% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
A number of research analysts have recently issued reports on the stock. BTIG Research boosted their price target on shares of Castle Biosciences from $38.00 to $50.00 and gave the stock a "buy" rating in a research note on Friday, December 12th. Weiss Ratings reiterated a "sell (d)" rating on shares of Castle Biosciences in a research report on Monday, December 29th. Guggenheim increased their target price on Castle Biosciences from $43.00 to $47.00 and gave the stock a "buy" rating in a research note on Monday, January 26th. Robert W. Baird lifted their price target on Castle Biosciences from $39.00 to $41.00 and gave the company an "outperform" rating in a research note on Tuesday, November 4th. Finally, Lake Street Capital upped their price objective on Castle Biosciences from $35.00 to $52.00 and gave the stock a "buy" rating in a report on Monday, January 12th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $47.14.
View Our Latest Stock Report on CSTL
About Castle Biosciences
(
Get Free Report)
Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company's proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.
The company's flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
